Post Traumatic Stress Disorder (PTSD) Clinical Trial
Official title:
A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder
Post Traumatic Stress Disorder (PTSD), is a devastating condition which causes distress or impairment in social, occupational or other important aspects of functioning. The occurrence of PTSD in the military is on the rise. This has significantly impacted military members, their families, and society as a whole. According to an expert panel convened by the Institute of Medicine in 2007, the effectiveness of most currently employed PTSD therapies is low. Safe and effective treatments are urgently needed. The specific aim of this investigation is to evaluate the effectiveness of a novel approach to relieve PTSD symptoms, utilizing a procedure commonly used in pain management, a Stellate Ganglion Block (SGB) with local anesthesia. Male soldiers experiencing moderate to severe symptoms of PTSD will be recruited for evaluation of Stellate Ganglion Block with local anesthesia as an intervention for PTSD treatment. Participants will be randomized to receive either the SGB with local anesthesia to C6 tubercle or a sham procedure involving a subcutaneous saline injection to the neck. The PTSD symptoms before and after the procedure will be measured using a comprehensive clinician-administered scale, self-report measures, objective measures of cognitive ability, and physiologic reactivity measures. Subjects will undergo assessment prior to the procedure, one week following the procedure, one month and 3 months following the procedure. Patients receiving sham injections will be allowed to cross over to the treatment group. Based on published case reports of Lipov et al in Chicago and Mulvaney et al from Walter Reed Medical Center, who utilized this technique to successfully treat soldiers with combat-related PTSD, we predict that the use of Stellate Ganglion Block will result in reduction of PTSD symptoms as measured by clinician-administered scales, self-report measures, objective measures of cognitive ability, and physiologic reactivity measures, leading to a significant and lasting reduction of PTSD symptoms.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00554177 -
A Clinical Trial for Post Traumatic Stress Disorder
|
Phase 1 | |
Recruiting |
NCT01545505 -
Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse
|
N/A | |
Completed |
NCT02966873 -
Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)
|
Phase 2 | |
Completed |
NCT04827056 -
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study
|
Phase 1 | |
Completed |
NCT04073862 -
The Norwegian Stepped-Care TF-CBT Study
|
N/A | |
Recruiting |
NCT05254379 -
Transcranial Direct Current Stimulation Treatment for Warriors Experiencing Chronic Pain
|
N/A | |
Terminated |
NCT02077972 -
Whole Body Hyperthermia & Combat-Related Posttraumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT04086654 -
Psychometric Properties of the International Trauma Interview (ITI) for ICD-11 PTSD and CPTSD
|
N/A | |
Completed |
NCT02723097 -
A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)
|
N/A | |
Withdrawn |
NCT00641511 -
Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)
|
Phase 2 | |
Recruiting |
NCT04558437 -
COVID-Impact "Psychological IMPACT of Covid-19 on AP-HP Staff"
|
||
Not yet recruiting |
NCT06162741 -
Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans
|
N/A | |
Completed |
NCT02764983 -
Occupational Therapy Driving Intervention for Returning Combat Veterans.
|
N/A | |
Completed |
NCT02765672 -
Effectiveness of a Driving Intervention on Safe Community Mobility for Returning Combat Veterans
|
N/A | |
Not yet recruiting |
NCT06335407 -
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
|
Phase 1 |